Dr. Reddy’s Allots 6,730 ESOP Shares, Expands Issued Capital
TipRanks' Prime Week Sale - 70% Off
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
The latest update is out from Dr Reddy’s Laboratories ( (RDY) ).
On June 19, 2026, Dr. Reddy’s Laboratories allotted 6,730 fully paid equity shares of Re.1 each to eligible employees under its 2002 employee stock option scheme and its 2007 ADR stock option scheme. The allotment followed the exercise of stock options and was disclosed to stock exchanges in India and the U.S., underscoring the company’s adherence to SEBI’s share-based employee benefit regulations.
Following this issuance, Dr. Reddy’s total issued share capital rose to Rs. 83.47 crore, represented by 83,46,76,800 issued shares of Re.1 each, with a small historical difference due to forfeited shares. The new shares rank pari passu with existing equity, implying minimal dilution while reinforcing long-term employee alignment and incentivisation, which may support retention and alignment of management with shareholder interests.
The most recent analyst rating on (RDY) stock is a Buy
with a $1540.00 price target.
To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock,
see the RDY Stock Forecast page.
Spark’s Take on RDY Stock
According to Spark, TipRanks’ AI Analyst, RDY is a Neutral.
The score is driven mainly by solid but weakening fundamentals (margin/ROE compression and higher debt despite growth) and a balanced earnings-call outlook that points to FY27 margin recovery but highlights near-term profitability and working-capital risks. Technicals are neutral-to-soft and valuation support is limited given the P/E and low yield.
To see Spark’s full report on RDY stock,
click here.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories is an India-based pharmaceutical company focused on developing, manufacturing and marketing generic medicines and related healthcare products. Its equity shares are listed in India on BSE and the National Stock Exchange, and its American Depositary Receipts trade on the New York Stock Exchange and NSE IFSC, giving it broad access to global capital markets.
The company operates under Indian and international securities regulations, including SEBI’s share-based employee benefit rules, reflecting its role as a major listed player in the global generics industry.
Average Trading Volume: 2,355,214
Technical Sentiment Signal: Buy
Current Market Cap: $11.25B
For detailed information about RDY stock, go to TipRanks’ Stock Analysis page.
